← Back to all signals
RESEARCH PAPER ANALYSIS

Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).

AI interpretation is pending for this paper.

Open original publication →
PMID41540924
JournalEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Publication Date2026-01-01
Ingested2026-08-02 12:06 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUNDRespiratory syncytial virus (RSV) is a leading cause of morbidity and mortality in young children and older adults. A long-acting anti-RSV monoclonal antibody (nirsevimab) and bivalent pre-fusion F-protein pregnancy vaccine became available to prevent RSV in young children in 2024; two RSV vaccines for adults ≥ 60 years were also available.AIMTo report 2024 RSV epidemiology in Australia, identify risk factors for severe outcomes, and use and effectiveness of RSV immunisation products.METHODSNational sentinel hospital-based RSV surveillance was established in 2024, recruiting hospitalised laboratory-confirmed RSV cases and test-negative controls from 22 sites in a national hospital network (FluCAN-PAEDS).RESULTSBetween April and December 2024, 3,998 subjects (3,415 children; 582 adults) were hospitalised with RSV. Most cases were infants < 12 months (n = 1,534; 38.4%); 1,661 (41.5%) had underlying medical conditions. Children < 6 months, First Nations children, those born preterm or with underlying medical conditions (cardiac, neurological, genetic and metabolic disease/disorders, immunosuppression) were at greatest risk of severe outcomes. Severe outcomes were more frequent in adults with malignancy, respiratory or cardiac disease. Nirsevimab effectiveness against hospitalisation in infants < 12 months in the two Australian jurisdictions with population-wide immunisation programmes was 83.1% (95% CI: 67.4-91.3). RSV vaccine use (pregnancy; adults ≥ 60 years) was limited, precluding effectiveness assessments.CONCLUSIONNational surveillance enabled timely 2024 data collection with the capability to evaluate effectiveness of immunisation products preventing RSV. Nirsevimab demonstrated comparable effectiveness to that in the northern hemisphere, informing Australia's 2025 strategy. Evaluation to assess the impact of more widespread uptake of RSV prevention products continues.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Mapping intratumoral heterogeneity in adolescent CNS tumors using simultaneous amide proton transfer-weighted signal and 18F-choline PET: A feasibility study. Neuro-oncology advances 57.5 2 Metastatic Neuroblastoma Presenting as Suspected Septic Arthritis: A Case Report. Cureus 52.3 3 Functional Impairment and Its Determinants in Adolescents With Inherited Bleeding Disorders: A Single-Centre Cross-Sectional Study. Cureus 62.0 4 A multimodal precision oncology platform integrating genomics, single-cell transcriptomics, and functional drug screening expands therapeutic options in pediatric brain tumors. bioRxiv : the preprint server for biology 69.2 5 Epigenetic patterns and methylation-based models for robust outcome prediction in osteosarcoma. medRxiv : the preprint server for health sciences 60.8 6 Association of Neuronal Cell Adhesion Molecule (NrCAM) Gene with Autism Spectrum Disorder in Indian Cohorts. Annals of neurosciences 60.0 7 State of Precision Oncology: An Australian Perspective. Journal of immunotherapy and precision oncology 72.9 8 Malignant Giant Cell Tumor of Bone: A Clinicopathological Analysis of 15 Cases. Human mutation 61.1 9 Clinically Suspected Tumefactive Demyelination Mimicking a Brain Tumor in a 10-Year-Old Boy: A Case Report. Clinical case reports 44.6 10 Beyond hemoglobin thresholds: identifying clinical predictors for red blood cell transfusion in pediatric severe anemia. Pediatric research 68.0 11 Distance and interruption: The violence of deportation among families enduring childhood cancer in the United States. Medical anthropology quarterly 56.4 12 Inverted Meckel's diverticulum in adults: two case reports and a systematic review. BMC gastroenterology 73.9 13 Torsion and infarction of a large pediatric mesenteric inflammatory myofibroblastic tumor: a case report. Journal of medical case reports 47.5 14 Preoperative Chemotherapy and Its Efficacy in Pediatric Wilms Tumor: A Systematic Review of Randomized Controlled Trials. Cureus 84.94 15 Fear of disease progression in primary caregivers of children with malignant solid tumors: a latent profile analysis. BMC psychology 66.9 16 Protracted copy number alteration evolution in Barrett's oesophagus leading to oesophageal cancer. medRxiv : the preprint server for health sciences 56.0 17 Editorial: The expanding spectrum of hemophagocytic lymphohistiocytosis: pathogenic mechanisms and therapeutic implications. Frontiers in immunology 33.09 18 DNA methylation profiling reveals novel rhabdomyosarcoma subsets with distinct histologic, genetic and clinical properties. medRxiv : the preprint server for health sciences 57.5 19 Brain microvascular endothelial cell dysfunction during Plasmodium infection does not result from astrocyte-derived wingless-related integration site (Wnt)7a deficiency. bioRxiv : the preprint server for biology 50.9 20 The role of microRNAs in neuroblastoma cell differentiation and their therapeutic potential: a systematic review. Frontiers in oncology 79.54 21 Temporal clinical trajectories and Day+14 landmark stratification of infection risk after CD19 CAR T-cell therapy. Frontiers in cellular and infection microbiology 71.52 22 Co-creating the EndoWatch - a smart wearable device for the management of hypothalamic dysfunction in pediatric brain tumor survivors: a pilot study. Frontiers in endocrinology 69.4 23 Ginsenoside RK3 suppresses osteosarcoma via PRMT5/GPX4-ferroptosis axis and enhances doxorubicin chemosensitivity. Frontiers in pharmacology 59.5 24 Age-dependent differences in SARS-CoV-2 entry-factor expression and innate immune responses between pediatric and adult liver organoids. Frontiers in public health 52.62 25 Health beliefs and parental responses to human papillomavirus vaccination in the Middle East: a theory-informed narrative synthesis guided by the health belief model. Frontiers in public health 81.12 26 Diagnostic potential of Aldo-keto reductase 1B10 in pediatric hepatic malignancies: a narrative, hypothesis-generating translational review based on adult evidence and future research directions. Frontiers in medicine 60.5 27 Mucormycosis beyond the classic host: a case series and narrative literature review from a tertiary Greek hospital. Frontiers in fungal biology 60.5 28 Incidence and mortality of breast cancer among adolescent and young adult women worldwide in 2022 and projections for 2040: Implications for surgery. Breast (Edinburgh, Scotland) 57.5 29 Dynamic Radiologic Severity Index is associated with antifungal treatment but does not independently predict initiation in pediatric acute lymphoblastic leukemia with post-chemotherapy pneumonia. Translational pediatrics 75.18 30 Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE)-like spectrum with a unique NRAS c.182A>G (p.Q61R) variant: a case report. Translational pediatrics 55.2 31 Predictive value of novel inflammatory markers for post-infectious pulmonary embolism in children. Translational pediatrics 61.2 32 Persistent cerebrospinal fluid tumor cells during transient radiographic response in bilateral retinoblastoma with central nervous system involvement: a pediatric case report. Translational pediatrics 57.42
PATIENT-FRIENDLY SUMMARY

Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic